Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Core Points - Plus Therapeutics, Inc. received a delinquency notification from Nasdaq due to delayed filing of its Quarterly Report for the period ended March 31, 2025 [1] - The company is required to submit a compliance plan by July 21, 2025, and if accepted, may receive an extension until November 17, 2025 [2] - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system [3] Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and is developing a pipeline of product candidates aimed at improving clinical outcomes for difficult-to-treat cancers [3] - The company combines image-guided local beta radiation with targeted drug delivery approaches, with lead programs in leptomeningeal metastases and recurrent glioblastoma [3] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [3]